Home > Haematology > ASH 2021 > Acute Myeloid Leukaemia > Improved risk stratification in MDS via gene-based scoring system

Improved risk stratification in MDS via gene-based scoring system

Presented By
Dr Elsa Bernard, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
ASH 2021
The newely developed molecular international prognosis scoring system for myelodysplastic syndromes (IPSS-M) delivers personalised, reproducible, and interpretable risk scores to stratify patients with MDS across 6 risk categories. The IPSS-M showed improved risk discrimination compared with the IPSS-R model and clear prognostic separation across risk categories [1]. “The current risk stratification methods for patients with MDS does not include gene mutations,” explained Dr Elsa Bernard (Memorial Sloan Kettering Cancer Center, NY, USA). “The IPSS-M was developed to improve risk stratification in MDS by considering clinical, cytogenetic, and genetic parameters.” The research team collected samples of 3,675 participants with blast percentages <20% and white blood cell count <13x109/L, representative of all IPSS-R risk categories. Subsequently, the associations between genetic mutations and leukaemia-free survival, overall survival, a...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on